Varian is taking a dive into the emerging world of cardiac radioablation through the acquisition of CyberHeart.
The purchase of the privately-held company includes the transfer of intellectual property and patents covering the use of radiation for the heart to Varian, which believes, based on early positive clinical findings, that the technology can assist cardiac arrhythmia patients.
"This is a new area and Varian is excited about the potential application of stereotactic radioablation to the cardiac space — specifically treating patients who are suffering from irregular heartbeats," Dr. Dee Khuntia, chief medical officer at Varian, told HCB News. "Based on the articles we have seen in the New England Journal of Medicine
and in Circulation
, we are enthused about this space."
“We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space."
Varian views its venture into cardiac ablation as an expansion of its focus on patient-centered innovation, and is now in the midst of prioritizing development and clinical trials going forward.
Cardiac ablation technology, however, is not yet approved by the FDA, as it still requires premarket approval (PMA), which subsequently requires additional clinical evidence as support.
"Varian has a long track record of innovations in the field of radiation medicine, and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions," said Khuntia. “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space."
Though the transfer of IP and software tools is part of the acquisition, no employees from CyberHeart will be joining Varian.
No financial details were disclosed.